The study will employ a combined laboratory-ambulatory design. Participants will engage in ambulatory assessment over the course of 14 days, wearing biosensors assessing transdermal alcohol concentration (TAC) and providing breathalyzer readings in real-world contexts. Also during this period, participants will attend three laboratory alcohol-administration sessions scheduled at one-week intervals, with alcohol dose and rate of consumption manipulated within and between participants, respectively. Laboratory visits will also double as ambulatory orientation, check-in, and close-out sessions.
21 years or older
drink alcohol at least 2x weekly
psychological or medical conditions that might contraindicate alcohol-administration
history of adverse reaction to type and amount of beverage used in the study
currently seeking treatment for alcohol use disorder
does not drink alcohol regularly
Regular healthy drinkers aged 21+
Other
Other
Alcohol
DrugAlcohol administered orally at multiple doses and consumption speeds to test transdermal device accuracy
Transdermal estimates of alcohol consumption
We will assess the accuracy of transdermal estimates of drinking vs sobriety
Transdermal estimates of drinking risk level
We will assess the accuracy of transdermal estimates of high risk drinking vs low risk drinking and sobriety
Transdermal estimates of blood alcohol concentration
We will assess the accuracy of transdermal estimates of blood alcohol concentration (BAC)
Click on the lead sponsor to view all of their trials.
University of Illinois at Urbana-Champaign
Lead sponsor
National Institutes of Health (NIH)
Collaborator
